Extraskeletal myxoid chondrosarcoma (EMC) is a very rare sarcoma most often arising in the soft tissue. Rare EMC of the bone have been reported. EMC exhibits distinctive clinico-pathological and genetic features; however, despite the name, it lacks any feature of cartilaginous differentiation. EMC is characterized by the rearrangement of the NR4A3, which, in most cases (about 62-75%), is fused with EWSR1 and less frequently with other partners, including TAF15 (27%), TCF12 (4%), TFG, and FUS. We herein report the identification by whole-transcriptome sequencing of HSPA8 as a novel fusion partner of NR4A3 in a case of EMC. FISH analysis confirmed the presence of a genomic HSPA8-NR4A3 translocation in the vast majority of tumor cells. Our findings expand the spectrum of NR4A3 fusion partners involved in EMC pathobiology.
Abstract
Extraskeletal myxoid chondrosarcoma (EMC) is a very rare sarcoma most often arising in the soft tissue. Rare EMC of the bone have been reported. EMC exhibits distinctive clinico-pathological and genetic features; however, despite the name, it lacks any feature of cartilaginous differentiation. EMC is characterized by the rearrangement of the NR4A3, which, in most cases (about 62-75%), is fused with EWSR1 and less frequently with other partners, including TAF15 (27%), TCF12 (4%), TFG, and FUS. We herein report the identification by whole-transcriptome sequencing of HSPA8 as a novel fusion partner of NR4A3 in a case of EMC. FISH analysis confirmed the presence of a genomic HSPA8-NR4A3 translocation in the vast majority of tumor cells. Our findings expand the spectrum of NR4A3 fusion partners involved in EMC pathobiology. The standard treatment of localized EMC is surgery with or without radiation therapy. When a medical therapy is needed, anthracyclinebased chemotherapy, trabectedin, and antiangiogenics have been shown to be active in a distinct proportion of EMC patients. [4] [5] [6] [7] EMC is characterized by the rearrangement of the NR4A3 gene, 8 which, in most cases (62-75%) is fused with EWSR1 as a result of a t(9;22)(q22;q12). [8] [9] [10] Less frequently, NR4A3 has been found rearranged with other partners, including TAF15 (27%), TCF12 (4%), TFG, and FUS. [8] [9] [10] [11] EMC with NR4A3 variant partners have been reported to have a more aggressive clinical course compared with the EWSR1-NR4A3 tumors, even though few clinical data are available to draw definitive conclusions. 11 The presence of NR4A3 rearrangement is an important diagnostic tool and helps in distinguishing EMC from other mimics.
Here we report the identification through RNA-sequencing profiling of a novel NR4A3 chimera in a case of EMC. 
| Whole-transcriptome sequencing
Total RNA was isolated from fresh frozen tumor tissue using the RNeasy spin-column method (Qiagen, Milan, Italy). Even though the tumor tissue was stored for long time before proceeding with RNA extraction, high-quality RNA was obtained and it was possible to synthesize whole transcriptome library in accordance with Illumina's TruSeq RNA Sample Prep v2 protocol (Illumina, San Diego, CA). Briefly, poly(A)-RNA molecules from 500 ng of total RNA were purified using oligo-dT magnetic beads. Following purification, the mRNA was fragmented and randomly primed for reverse transcription followed by second-strand synthesis to create double-stranded cDNA fragments.
These cDNA fragments went through a terminal-end repair process and ligation using paired-end sequencing adapters. The products were then amplified to enrich for fragments carrying adapters ligated on both ends and to add additional sequences complementary to the oligonucleotides on the flow cell, thus creating the final cDNA library.
12pM paired-end libraries were amplified and ligated to the flowcell by bridge PCR, and sequenced at 2 3 80 bp read length, using Illumina
Sequencing by synthesis technology. Reads were mapped on the human reference genome by TopHat/BowTie pipeline. For fusion transcript discovery, three bioinformatics tools were used: DeFuse, ChimeraScan, and FusionMap.
| Fusion data validation
About 500 ng of total RNA was retrotranscribed to cDNA using First Strand cDNA Sythesis kit (Roche) and oligo-dT primers, then the fusion 
| Gene expression
For NR4A3 mRNA expression evaluation starting from wholetranscriptome sequencing (WTS) data, normalized read counts were determined for each coding position of cDNA. For relative quantification of NR4A3 mRNA, realtime PCR was performed in the case and in other 11 NRA43 translocated EMCS (5 EWSR and 6 TAF15 fused).
Primer used were NR4A3_ex5_Fw 5 0 -ACTGCCCAGTAGACAAGAG ACG-3 0 and NR4A3_ex6_rev 5 0 -GTTTGGAAGGCAGACGACCTCT-3 0 .
Expression level was normalized against two housekeeping genes, ATPS and GUSB, using DCt method.
| FISH
FISH analysis was performed on frozen tumor tissue to confirm the translocation between the HSPA8 and NR4A3 genes, using three BlueFISH probes (BlueGnome Ltd., Cambridge). In detail, the BAC clone RP11-1103M6 (in orange) for the NR4A3 gene and the clones RP11-953P6 and the RP11-1068F18 (in green) for HSPA8 were used.
FISH analysis was performed according to the manufacturer's instructions.
| R E S U L T S 3.1 | HSPA8-NR4Afusion description
WTS was performed on one case of EMC that, although involving NR4A3, was negative for both EWSR and TAF15 rearrangements.
Fusion transcript analysis highlighted the presence of a novel chimeric RNA involving HSPA8, mapping to 11q24.1, and NR4A3. This fusion gene was detected by all three bioinformatic tools used and was supported by a relevant number of reads (respectively 95 split and 53 spanning reads across the junction). The breakpoint involved exon 2 of HSPA8 and exon 4 of NR4A3 ( Figure 3A) . The fusion retained the reading frame and encoded for a chimeric protein with the whole coding sequence of NR4A3 fused to the promoter region of HSPA8. The breakpoint was validated and confirmed using RT-PCR followed by direct sequencing ( Figure 3B ). FISH analysis confirmed the presence of the HSPA8-NR4A3 genomic translocation in the vast majority of tumor cells (>90%) ( Figure 3C ). No fusion transcripts other than HSPA8-NR4A3 was detected by any of the algorithms used.
| NR4A3 expression level
We next assessed the expression level of NR4A3. The normalized count of reads overlapping NR4A3 showed that the exomic regions downstream of the breakpoint were overexpressed compared to the ones upstream, indicating that HSPA8-NR4A3 fusion produced an increase of NR4A3 expression ( Figure 4A ). Moreover, qRT-PCR performed on 3 0 exons of NR4A3 showed that the HSPA8-fused case had FIG URE 3 HSPA8-NR4A3 fusion found in an EMC case. A, Schematic representation of fusion event between HSPA8 (orange) and NR4A3 (blue). Empty and full boxes represent non-coding and coding exons, respectively. B, Sanger sequencing validation of the fusion breakpoint. C, FISH validation of the t(9;11)(q22;q24) translocation. In the upper panel, a schematic representation of the three used probes is shown. In the lower panel an illustrative fusion positive cell is shown: about 95% of tumor cells showed a signal pattern consisting of one orange/green fusion signal, one orange signal, and one green signal, indicating the t(9;11), the normal 9q22 locus and the normal 11q24 locus, respectively.
an extremely high expression of NR4A3 in comparison with 11 EMC with other NRA43 fusions (EWSR1 or TAF15) ( Figure 4B ).
| DISCUSSION
We herein report on a novel fusion between NR4A3 and HSPA8 detected in EMC arising from the soft tissue of the inguinal region of a 60-year-old woman. NR4A3, also known as NOR1, belongs to the highly conserved NR4A subfamily of orphan nuclear hormone receptors. 12 These types of receptors are constitutively active, ligandindependent transcription factors, and positively regulate target gene expression by binding to NBRE elements. NR4A3 has been implicated in regulating key cellular functions, including proliferation, cell survival, and inflammation. [11] [12] [13] Rearrangements of NR4A3 represent the genetic hallmark of EMC. 8 About two third of EMC harbors the translocation t(9;22)(q22;q12) resulting in the fusion of EWSR1 with NR4A3, while about a third of the cases carry a TAF15-NR4A3 fusion. More rarely EMC featuring TCF12, TFG, or FUS as fusion partner of NR4A3
have been reported. [8] [9] [10] [11] In all types of fusions reported so far, NR4A3
is broken in proximity of the ATG start codon, thus retaining the whole coding sequence. 10 As a result of these fusions, the NR4A3 gene falls under the promoter region of the partner gene. Moreover, when fused with EWSR1 and of TAF15, the chimeric protein acquires the transactivation domain of the partner gene.
In the HSPA8-NR4A3 fusion described herein, The incidence of the HSPA8-NR4A3 fusion in EMC, as well as its impact on EMC clinico-pathological behavior, needs to be assessed in larger series, although it likely represents a rare event.
In conclusions, we have identified a novel partner of NR4A3 in a case of EMC, thus expanding the spectrum of NR4A3 partners involved in EMC biology.
